Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS (AVATAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01245803
Recruitment Status : Unknown
Verified July 2010 by Beijing Anzhen Hospital.
Recruitment status was:  Recruiting
First Posted : November 23, 2010
Last Update Posted : November 23, 2010
Information provided by:
Beijing Anzhen Hospital

Brief Summary:
Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI

Condition or disease Intervention/treatment Phase
Acute Coronary Syndrome Angioplasty Drug: additional rosuvastatin loading Drug: placebo control Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome
Study Start Date : April 2010
Estimated Primary Completion Date : April 2011
Estimated Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: rosuvastatin,one month,lipid lowering
additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
Drug: additional rosuvastatin loading
additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI

Placebo Comparator: sugar pill, one month
sugar pill is given 18-24hr and 4-6hr before PCI as control
Drug: placebo control
sugar pill is given 18-24hr and 4-6hr before PCI as control

Primary Outcome Measures :
  1. peri-procedural myocardial damage [ Time Frame: 48 hours after PCI ]

Secondary Outcome Measures :
  1. MACE [ Time Frame: 30 days after PCI ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18-75 year old
  • diagnosed as acute coronary syndrome
  • Plan to PCI

Exclusion Criteria:

  • STEMI patient
  • emergency PCI(<2h) for NSTE-ACS
  • History of liver disease and myopathy (ALT/AST>3 x upper limit of normal,CK>5 x upper limit of normal)
  • TG>500mg/dl,CCr<30ml/min
  • inflammatory disease
  • allergic to rosuvastatin
  • nephrotic syndrome,hypothyroidism,systemic lupus erythematosus,myeloma,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01245803

Layout table for location contacts
Contact: Shujjuan Cheng, MD, PhD +861064456995
Contact: Shiying Li, MD +861064456541

Layout table for location information
China, Beijing
the 28th division, Beijing Anzhen Hospital Recruiting
Beijing, Beijing, China, 100029
Sponsors and Collaborators
Beijing Anzhen Hospital

Layout table for additonal information
Responsible Party: HYan, BeijingAnzhen Identifier: NCT01245803    
Other Study ID Numbers: 6998
First Posted: November 23, 2010    Key Record Dates
Last Update Posted: November 23, 2010
Last Verified: July 2010
Keywords provided by Beijing Anzhen Hospital:
acute coronary syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Coronary Syndrome
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors